CND Life Sciences
Scottsdale, US · Founded 2017 · Delaware corporation · 2 known investors
Find your way into CND Life Sciences
225 people in our graph share verified history with the CND Life Sciences team — schools, employers, funds. One of them is your warm intro.
Scott Raneyunlockedknows Peter Harris · together at Duke University (overlapped)
×6knows the team · via Duke University
knows the team · via University of Arizona
×3knows the team · via Haverford College
knows the team · via The Associated Press
CND Life Sciences develops skin-based neurodiagnostic tests, including a test to detect abnormal alpha-synuclein in skin biopsies to help physicians diagnose Parkinson's disease and related synucleinopathies. It operates a CLIA-certified and CAP-accredited pathology lab serving clinicians and patients.
Founders & leadership
CND Life Sciences was founded in 2017 by Todd Levine.
TL
Todd LevineinFounder · Chief Medical OfficerTodd Levine is a clinical neurologist with over 30 years of experience, including 15+ years developing diagnostic tests for neurological diseases, and served as Director of Preventative Neurology at HonorHealth before joining CND Life Sciences.
RJ
Richard J. MorelloExecutive
PH
Peter HarrisinDirectorPeter Harris is an executive officer and director at CND Life Sciences, which develops skin-based neurodiagnostic tests to help physicians diagnose Parkinson's disease and related conditions.
CG
Christopher GibbonsNamed on SEC filing
Board
JS
Jack SeaverBoard director
EC
Enrique CarrazanaBoard director
RF
Roy FreemanBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$30M disclosed across 7 rounds · 2021–2026
▶$6.3MraisedAug 2026 · 14 investors · BiotechnologyRule 506(b)
▶$6.3MraisedAug 2026 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard J. MorelloExecutive Officer, Director
- Todd LevineExecutive Officer, Director
- Peter HarrisExecutive Officer, Director
- Enrique CarrazanaDirector
- Christopher GibbonsDirector
- Jack SeaverDirector
- Offering amount
- $6.3M
- Amount sold
- $6.3M
- Minimum investment
- $25K
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.6MraisedMay 2025 · 38 investors · BiotechnologyRule 506(b)
▶$8.6MraisedMay 2025 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard J. MorelloExecutive Officer, Director
- Todd LevineExecutive Officer, Director
- Jack SeaverDirector
- Peter HarrisExecutive Officer, Director
- Enrique CarrazanaDirector
- Christopher GibbonsDirector
- Offering amount
- $9M
- Amount sold
- $8.6M
- Minimum investment
- $25K
- Sales commissions
- $36K
- Placement agents
- Finalis Securities
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedMar 2024 · 22 investors · BiotechnologyRule 506(b)
▶$2MraisedMar 2024 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter HarrisDirector
- Richard J. MorelloExecutive Officer, Director
- Enrique CarrazanaDirector
- Todd LevineExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $2M
- Minimum investment
- $25K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedJul 2023 · 19 investors · BiotechnologyRule 506(b)
▶$1.5MraisedJul 2023 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Enrique CarrazanaDirector
- Richard J. MorelloExecutive Officer, Director
- Peter HarrisExecutive Officer, Director
- Todd LevineDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedMar 2023 · 26 investors · BiotechnologyRule 506(b)
▶$4.5MraisedMar 2023 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Todd LevineExecutive Officer, Director
- Richard J. MorelloExecutive Officer, Director
- Peter HarrisExecutive Officer, Director
- Enrique CarrazanaDirector
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedNov 2021 · 22 investors · BiotechnologyRule 506(b)
▶$4.2MraisedNov 2021 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter HarrisDirector
- Enrique CarrazanaDirector
- Todd LevineDirector
- Richard J. MorelloExecutive Officer, Director
- Roy FreemanDirector
- Offering amount
- $5M
- Amount sold
- $4.2M
- Minimum investment
- $50K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2.9MraisedApr 2021 · 20 investors · BiotechnologyRule 506(b)
▶$2.9MraisedApr 2021 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roy FreemanDirector
- Todd LevineDirector
- Peter HarrisDirector
- Richard J. MorelloExecutive Officer, Director
- Christopher GibbonsDirector
- Offering amount
- $2.9M
- Amount sold
- $2.9M
- Minimum investment
- $50K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with CND Life Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2.4M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
VC funding deals: CND Life Sciences, JIJ, Actualyze AI - InfotechLeadinfotechlead.com · Aug 2026Frequently asked questions
- What does CND Life Sciences do?
- CND Life Sciences develops skin-based neurodiagnostic tests, including a test to detect abnormal alpha-synuclein in skin biopsies to help physicians diagnose Parkinson's disease and related synucleinopathies. It operates a CLIA-certified and CAP-accredited pathology lab serving clinicians and patients.
- Who founded CND Life Sciences?
- CND Life Sciences was founded by Todd Levine in 2017.
- Who are CND Life Sciences's investors?
- CND Life Sciences's investors include BlueStone Venture Partners, Top Corner Capital.
- How much funding has CND Life Sciences raised?
- CND Life Sciences has disclosed $30M raised across 7 rounds.
- Where is CND Life Sciences headquartered?
- CND Life Sciences is headquartered in Scottsdale, US.